All In Biotech

Drug Trial Radar · NCT05562466

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Double-blind, Randomized, Active-controlled, Two-way Cross-over Study, With 12-week Treatment Duration Per Period, to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate / Mometasone Furoate) Compared to Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

May 11, 2023

Primary completion

Feb 1, 2028

Study completion May 30, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the superiority in terms of efficacy and evaluate the safety of QMF149 (indacaterol (acetate) / mometasone (furoate)) compared to budesonide in children from 6 to less than 12 years of age with asthma. * The study duration will be up to 37 weeks including an investigational treatment duration of 12 weeks and a comparator treatment duration of 12 weeks. * The visit frequency will be 3 weeks for screening, run-in and wash-out period, 6 weeks interval for visits during each treatment period, 30 days for safety follow-up.

Conditions

  • Asthma

Interventions

  • QMF149Drug

    QMF149 75/40 μg o.d via Breezhaler

  • BudesonideDrug

    Budesonide 200 μg o.d via Breezhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in trough FEV1Time frame: Week 12 of each treatment period

Locations

65 sites in 17 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Mendoza, Mendoza Province, Argentina · Recruiting

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Novartis Investigative Site

    Graz, Austria · Withdrawn

  • Novartis Investigative Site

    Salzburg, Austria · Withdrawn

  • Novartis Investigative Site

    Sankt Pölten, Austria · Withdrawn

  • Novartis Investigative Site

    Brasília, Federal District, Brazil · Recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    Sorocaba, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Rousse, Bulgaria · Recruiting

  • Novartis Investigative Site

    Sevlievo, Bulgaria · Recruiting

  • Novartis Investigative Site

    Bucaramanga, Santander Department, Colombia · Recruiting

  • Novartis Investigative Site

    Ibague, Tolima Department, Colombia · Recruiting

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia · Recruiting

  • Novartis Investigative Site

    Plzen Bory, Czechia · Withdrawn

  • Novartis Investigative Site

    Prague, Czechia · Withdrawn

  • Novartis Investigative Site

    Athens, Greece · Recruiting

  • Novartis Investigative Site

    Chaïdári, Greece · Withdrawn

  • Novartis Investigative Site

    Heraklion Crete., Greece · Recruiting

  • Novartis Investigative Site

    Pátrai, Greece · Active not recruiting

  • Novartis Investigative Site

    Thessaloniki, Greece · Recruiting

  • Novartis Investigative Site

    Guatemala City, Guatemala · Recruiting

  • Novartis Investigative Site

    Guatemala City, GTM, Guatemala · Recruiting

  • Novartis Investigative Site

    Budapest, Hungary · Recruiting

  • Novartis Investigative Site

    Gödöllő, Hungary · Recruiting

  • Novartis Investigative Site

    Szeged, Hungary · Recruiting

  • Novartis Investigative Site

    Szigetvár, Hungary · Recruiting

  • Novartis Investigative Site

    Naples, Italy · Recruiting

  • Novartis Investigative Site

    Brescia, BS, Italy · Withdrawn

  • Novartis Investigative Site

    Catania, CT, Italy · Recruiting

  • Novartis Investigative Site

    Florence, FI, Italy · Withdrawn

  • Novartis Investigative Site

    Pavia, PV, Italy · Withdrawn

  • Novartis Investigative Site

    Roma, RM, Italy · Recruiting

  • Novartis Investigative Site

    Querétaro, Mexico · Recruiting

  • Novartis Investigative Site

    Guadalajara, Jalisco, Mexico · Recruiting

  • Novartis Investigative Site

    Guadalajara, Jalisco, Mexico · Recruiting

  • Novartis Investigative Site

    San Juan del Río, Querétaro, Mexico · Recruiting

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.